Those findings suggest, that enhanced bioavailability of oligopeptides determined by the PEPT1 enterocyte content may not only affect pharmacokinetics of its drug substrates, but also could be partially a risk factor for progression of chronic renal failure related to the dietary protein exposure. Here, SLC15A1 is linked to chronic kidney disease.